{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:48:11Z","timestamp":1774936091648,"version":"3.50.1"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with adrenal insufficiency due to 21-hydroxylase deficiency (21-OHD) are often exposed to supraphysiologic doses of glucocorticoids (GCs), which can augment metabolic dysfunction by altering glucose, lipid and protein metabolism. Exogenous GCs also fail to mimic the natural circadian rhythm of cortisol secretion. MicroRNAs (miRNAs) are important regulators of gene expression involved in various biological and pathological processes. GCs can regulate miRNAs and in turn miRNAs can modulate GC receptor (GR) activity influencing GR-mediated activity. In this pilot study, we examine the effects of exogenous GCs on circulating miRNA levels in patients with adrenal insufficiency due to classic 21-OHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients\/methods<\/jats:title>\n                    <jats:p>\n                      Blood samples were collected from 37 patients with classic 21-OHD. Comprehensive miRNA-seq transcriptomic profiling was performed followed by functional enrichment analysis. Patients on different GC types (short-\n                      <jats:italic>vs.<\/jats:italic>\n                      long-acting) and on different GC doses (physiologic, moderate, or high dose;&amp;lt;12 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day, 12-18 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day, &amp;gt;18 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day hydrocortisone equivalents (HCe), respectively) were compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven miRNAs (hsa-miR-320a, hsa-miR-122, hsa-let-7b, hsa-let-7i, hsa-miR-4747, hsa-miR3591, hsa-miR-4732) were differentially expressed in patients receiving high-dose GC therapy compared to those receiving physiologic doses (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Expression of all 7 miRNAs was negatively correlated with GC dose (\n                      <jats:italic>P<\/jats:italic>\n                      \u2264 0.03). Gene ontology enrichment and KEGG pathway analyses of sequencing results found that the differentially expressed miRNAs were involved in cell cycle progression and proliferation, insulin signaling, metabolic dysfunction, circadian rhythm, and GR signaling. Furthermore, MIENTURNET integrative pathway and network analyses of miRNAs identified 470 target genes, many of which play a role in insulin sensitivity, lipid metabolism, gluconeogenesis, oxidative stress and\/or tumor metabolism. Conversely, no differences were observed in miRNA profiles between patients who were on short-acting compared to long-acting GCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In patients with CAH, daily GC dose &amp;gt; 18 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day HCe impacts the expression of miRNAs that are known to be associated with GCs and their biological effects. The identification of a distinct circulating miRNA signature associated with supraphysiologic GC exposure in patients with CAH suggests that miRNAs could emerge as a valuable non-invasive biomarker for detecting GC excess and monitoring treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1784619","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:11:06Z","timestamp":1774930266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exogenous glucocorticoid dose impacts circulating microRNA expression in patients with adrenal insufficiency due to 21-hydroxylase deficiency"],"prefix":"10.3389","volume":"17","author":[{"given":"Vipula","family":"Kolli","sequence":"first","affiliation":[{"name":"Department of Pediatrics, National Institutes of Health Clinical Center","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Trick","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Institutes of Health Clinical Center","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Schulman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Institutes of Health Clinical Center","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R","family":"Iben","sequence":"additional","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Padilla","sequence":"additional","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianwei","family":"Li","sequence":"additional","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Rueda","family":"Faucz","sequence":"additional","affiliation":[{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development","place":["Bethesda, MD, United States"]},{"name":"Hospital for Endocrine Surgery Research Center, HCA Florida Healthcare, HCA Healthcare Research Institute","place":["Tampa, FL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah P.","family":"Merke","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Institutes of Health Clinical Center","place":["Bethesda, MD, United States"]},{"name":"The Eunice Kennedy Shriver National Institute of Child Health and Human Development","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909786","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"383","author":"Merke","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31431-9","article-title":"Congenital adrenal hyperplasia","volume":"390","author":"El-Maouche","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01545","article-title":"A general introduction to glucocorticoid biology","volume":"10","author":"Timmermans","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R117.000366","article-title":"The role of microRNAs in glucocorticoid action","volume":"293","author":"Clayton","year":"2018","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2380","article-title":"Modified-release hydrocortisone to provide circadian cortisol profiles","volume":"94","author":"Debono","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa002","article-title":"Dynamics of ACTH and cortisol secretion and implications for disease","volume":"41","author":"Lightman","year":"2020","journal-title":"Endocr Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/endrev\/bnae024","article-title":"The cortisol awakening response: regulation and functional significance","volume":"46","author":"Stalder","year":"2025","journal-title":"Endocr Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of microRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O\u2019Brien","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708765","article-title":"Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications","volume":"11","author":"Otmani","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.300144","article-title":"MicroRNAs in metabolic disease","volume":"33","author":"Fernandez-Hernando","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.620012","article-title":"Circulating microRNA expression in Cushing\u2019s syndrome","volume":"12","author":"Vetrivel","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2022.5208","article-title":"Role of microRNAs and long non\u2212coding RNAs in glucocorticoid signaling(Review)","volume":"50","author":"Pierouli","year":"2022","journal-title":"Int J Mol Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.vh.2023.06.006","article-title":"MicroRNA regulation of adrenal glucocorticoid and androgen biosynthesis","volume":"124","author":"Azhar","year":"2024","journal-title":"Vitam Horm"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygcen.2013.02.012","article-title":"Expression and regulation of miR-17a and miR-430b in zebrafish ovarian follicles","volume":"188","author":"Abramov","year":"2013","journal-title":"Gen Comp Endocrinology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.812438","article-title":"Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen","volume":"293","author":"McFall","year":"2018","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2199-10-13","article-title":"Sex-different and growth hormone-regulated expression of microRNA in rat liver","volume":"10","author":"Cheung","year":"2009","journal-title":"BMC Mol Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf546","article-title":"Clinical and biochemical phenotype across the genotypic spectrum of 21-hydroxylase deficiency in 457 individuals","volume":"111","author":"Lao","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.beem.2008.10.010","article-title":"Management of the child with congenital adrenal hyperplasia","volume":"23","author":"Hindmarsh","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.106.4.767","article-title":"Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth","volume":"106","author":"Rivkees","year":"2000","journal-title":"Pediatrics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2102","article-title":"Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia","volume":"97","author":"Finkielstain","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80128-3","article-title":"Cortisol production rate in childhood and adolescence","volume":"117","author":"Linder","year":"1990","journal-title":"J Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1210\/jcem-72-1-39","article-title":"Daily cortisol production rate in man determined by stable isotope dilution\/mass spectrometry","volume":"72","author":"Esteban","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae824","article-title":"Adult height following prepubertal treatment with antiandrogen, aromatase inhibitor, and reduced hydrocortisone in CAH","volume":"110","author":"Merke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404656","article-title":"Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia","volume":"391","author":"Auchus","year":"2024","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2404655","article-title":"Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia","volume":"391","author":"Sarafoglou","year":"2024","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2109","article-title":"Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty","volume":"92","author":"Bonfig","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jpeds.2014.01.011","article-title":"Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort","volume":"164","author":"Sarafoglou","year":"2014","journal-title":"J Pediatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad431","article-title":"DIANA-miRPath v4.0: expanding target-based miRNA functional analysis in cell-type and tissue contexts","volume":"51","author":"Tastsoglou","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s12859-019-3105-x","article-title":"MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis","volume":"20","author":"Licursi","year":"2019","journal-title":"BMC Bioinf"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-1335","article-title":"MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain","volume":"150","author":"Vreugdenhil","year":"2009","journal-title":"Endocrinology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-011-0072-8","article-title":"Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma","volume":"2","author":"Tessel","year":"2011","journal-title":"Horm Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i44.7947","article-title":"MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases","volume":"19","author":"De Iudicibus","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04122-z","article-title":"miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signalling pathway","volume":"86","author":"Lucafo","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020276","article-title":"miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis","volume":"9","author":"Condrat","year":"2020","journal-title":"Cells"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23020","article-title":"Circulating microRNA expression profiling and bioinformatics analysis of patients with coronary artery disease by RNA sequencing","volume":"34","author":"Zhong","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B41","doi-asserted-by":"publisher","first-page":"25997","DOI":"10.1038\/srep25997","article-title":"microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection","volume":"6","author":"Hamam","year":"2016","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab733","article-title":"DIANA-miTED: a microRNA tissue expression database","volume":"50","author":"Kavakiotis","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1996","article-title":"Circulating miRNA profiles in patients with metabolic syndrome","volume":"97","author":"Karolina","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041051","article-title":"Circulating miR-320a as a predictive biomarker for left ventricular remodelling in STEMI patients undergoing primary percutaneous coronary intervention","volume":"9","author":"Galeano-Otero","year":"2020","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1038\/s41598-017-05001-z","article-title":"MiR-320a as a potential novel circulating biomarker of arrhythmogenic cardioMyopathy","volume":"7","author":"Sommariva","year":"2017","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/nu11122890","article-title":"Circulating miRNAs as biomarkers of obesity and obesity-associated comorbidities in children and adolescents: A systematic review","volume":"11","author":"Oses","year":"2019","journal-title":"Nutrients"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-021-00842-1","article-title":"Circulating microRNAs 34a, 122, and 192 are linked to obesity-associated inflammation and metabolic disease in pediatric patients","volume":"45","author":"Lischka","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0197637","DOI":"10.1371\/journal.pone.0197637","article-title":"Increased circulating microRNA-122 is a biomarker for discrimination and risk stratification in patients defined by sepsis-3 criteria","volume":"13","author":"Rahmel","year":"2018","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1038\/s41598-017-11405-8","article-title":"Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals","volume":"7","author":"Murray","year":"2017","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2012.838","article-title":"Circulating microRNA-122 as a potential biomarker for liver injury","volume":"5","author":"Ding","year":"2012","journal-title":"Mol Med Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00215","article-title":"MicroRNA let-7i is a promising serum biomarker for post-stroke cognitive impairment and alleviated OGD-induced cell damage in vitro by regulating bcl-2","volume":"14","author":"Wang","year":"2020","journal-title":"Front Neurosci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5093803","DOI":"10.1155\/2019\/5093803","article-title":"Circulating microRNAs as novel potential biomarkers for left ventricular remodeling in postinfarction heart failure","volume":"2019","author":"Gao","year":"2019","journal-title":"Dis Markers"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00132","article-title":"Identification of neuroendocrine stress response-related circulating microRNAs as biomarkers for type 2 diabetes mellitus and insulin resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2377-13-178","article-title":"Circulating miR-30a, miR-126 and let-7b as biomarker for ischemic stroke in humans","volume":"13","author":"Long","year":"2013","journal-title":"BMC Neurol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2023.13090","article-title":"Serum\u2212derived exosomal hsa\u2212let\u22127b\u22125p as a biomarker for predicting the severity of coronary stenosis in patients with coronary heart disease and hyperglycemia","volume":"28","author":"Han","year":"2023","journal-title":"Mol Med Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1151855","article-title":"The let-7b-5p, miR-326, and miR-125a-3p are associated with left ventricular systolic dysfunction in post-myocardial infarction","volume":"10","author":"Dantas-Komatsu","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11101955","article-title":"MicroRNA-4732-3p is dysregulated in breast cancer patients with cardiotoxicity, and its therapeutic delivery protects the heart from doxorubicin-induced oxidative stress in rats","volume":"11","author":"Sanchez-Sanchez","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9060591","article-title":"MicroRNA 320, an anti-oncogene target miRNA for cancer therapy","volume":"9","author":"Liang","year":"2021","journal-title":"Biomedicines"},{"key":"B59","article-title":"Overview of microRNAs as diagnostic and prognostic biomarkers for high-incidence cancers in 2021","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645475","article-title":"Circulating miR-320a acts as a tumor suppressor and prognostic factor in non-small cell lung cancer","volume":"11","author":"Khandelwal","year":"2021","journal-title":"Front Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13578-020-00443-x","article-title":"MicroRNA let-7b inhibits cell proliferation via upregulation of p21 in hepatocellular carcinoma","volume":"10","author":"Hui","year":"2020","journal-title":"Cell Biosci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092415","article-title":"The roles of the let-7 family of microRNAs in the regulation of cancer stemness","volume":"10","author":"Ma","year":"2021","journal-title":"Cells"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms141123086","article-title":"Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells","volume":"14","author":"Bao","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02457-w","article-title":"Tumor-derived exosomes deliver the tumor suppressor miR-3591-3p to induce M2 macrophage polarization and promote glioma progression","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"B65","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.resmer.2021.100865","article-title":"MicroRNA-4732 is downregulated in non-small cell lung cancer and inhibits tumor cell proliferation, migration, and invasion","volume":"80","author":"Tang","year":"2021","journal-title":"Respir Med Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2009.05207.x","article-title":"CHANGES IN microRNA (miR) profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes","volume":"36","author":"Ling","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-025-04077-1","article-title":"AMSC\/CXCR4-derived exosomes and miRNA-320 regulate pathological angiogenesis in diabetes","volume":"194","author":"Wu","year":"2025","journal-title":"Ir J Med Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.144576","article-title":"MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia","volume":"285","author":"Sepramaniam","year":"2010","journal-title":"J Biol Chem"},{"key":"B69","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12902-025-01888-2","article-title":"The predictive function of miR-122-5p and its action mechanism by regulating PKM2 in metabolic syndrome","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62236.sa2","article-title":"Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial","volume":"10","author":"Chantzichristos","year":"2021","journal-title":"Elife"},{"key":"B71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/2211536612666221205144321","article-title":"Expression of circulating microRNAs associated with obesity and their relationships with biochemical parameters and health-related physical fitness in children 6 to 10 years old in Cali, Colombia","volume":"12","author":"Rico-Florez","year":"2023","journal-title":"Microrna"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2023-0320","article-title":"MicroRNA-29a and microRNA-122 expressions and other inflammatory markers among obese children with diabetes","volume":"37","author":"Bayoumy","year":"2024","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B73","doi-asserted-by":"publisher","first-page":"116692","DOI":"10.1016\/j.bcp.2024.116692","article-title":"Implication of Let7b\/AhR\/ARNT\/HMGB1\/RAGE cascade in neuroplasticity disturbances induced by glucocorticoids and the promising reversible effect of 3,3 diindolymethane: Bidirectional crosstalk of Aryl hydrocarbon receptors","volume":"232","author":"Abd-Elmawla","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115673","article-title":"Identification of microRNAs associated with prediabetic status in obese women","volume":"24","author":"Kovac","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"100784","DOI":"10.1016\/j.bj.2024.100784","article-title":"miRNA-mediated regulation of clock gene expression in men and women with colorectal cancer and possible consequences for disease management","volume":"48","author":"Herichova","year":"2025","journal-title":"BioMed J"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1165230","article-title":"Circadian glucocorticoids throughout development","volume":"17","author":"Lehmann","year":"2023","journal-title":"Front Neurosci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.737890","article-title":"MicroRNA-433 dampens glucocorticoid receptor signaling, impacting circadian rhythm and osteoblastic gene expression","volume":"291","author":"Smith","year":"2016","journal-title":"J Biol Chem"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3858\/emm.2009.41.9.070","article-title":"Comprehensive analysis of microRNA-mRNA co-expression in circadian rhythm","volume":"41","author":"Na","year":"2009","journal-title":"Exp Mol Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1511520","article-title":"Evaluation of microRNAs as liquid biopsy markers in adrenocortical tumors","volume":"16","author":"Mytareli","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1073328","article-title":"Heterogeneous circulating miRNA profiles of PBMAH","volume":"13","author":"Hara","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147676","article-title":"Characterization of adrenal miRNA-based dysregulations in Cushing\u2019s syndrome","volume":"23","author":"Vetrivel","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00331","article-title":"Circulating plasma microRNA to differentiate cushing\u2019s disease from ectopic ACTH syndrome","volume":"11","author":"Belaya","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01005-8","article-title":"Circulating non-coding RNA biomarkers of endocrine tumours","volume":"20","author":"Butz","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab051","article-title":"Modified-release hydrocortisone in congenital adrenal hyperplasia","volume":"106","author":"Merke","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404656","article-title":"Crinecerfont in adult congenital adrenal hyperplasia","volume":"391","author":"Auchus","year":"2024","journal-title":"Reply. N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1784619\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:11:10Z","timestamp":1774930270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1784619\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":85,"alternative-id":["10.3389\/fendo.2026.1784619"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1784619","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1784619"}}